Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
View original at finance.yahoo.comCell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals Precedence Research This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Yescarta is currently one of the top-selling therapies in the CAR-T category
80% confidenceAs of 2025, there are 36 approved gene therapies globally and 71 non-genetically modified cell therapies
80% confidenceZolgensma is one of the highest-grossing gene therapies in the world
80% confidence9 new gene and cell therapies were approved by the FDA in 2024
80% confidenceThere are 46 FDA-approved cell and gene therapies in the U.S.
80% confidenceThe cell and gene therapy market will hit $232.22 billion by 2035, driven by a CAGR of 24% over the forecast period
80% confidenceZolgensma projected sales are estimated at $510 million by 2027
80% confidenceIndia's growing role in global gene therapy production is evidenced by Bharat Biotech's expansion into gene therapies and CGT manufacturing capabilities
80% confidenceThe FDA has approved 7 distinct CAR-T products
80% confidence
Data points we hold from this source
| U.S. Food and Drug Administration · approved car t products | 7 products |
| U.S. Food and Drug Administration · approved gene therapies global | 36 products |
| U.S. Food and Drug Administration · approved non modified cell therapies | 71 products |
| U.S. Food and Drug Administration · new approvals | 9 products |